Malta - angleščina - Malta Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - ursodeoxycholic acid - capsule - ursodeoxycholic acid 250 mg - bile and liver therapy

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - ursodeoxycholic acid 250mg;  ;   - capsule - 250 mg - active: ursodeoxycholic acid 250mg     excipient: capsugel white op colloidal silicon dioxide magnesium stearate maize starch pregelatinised maize starch - ursosan is indicated in the treatment of chronic cholestatic liver diseases, including primary biliary cirrhosis (pbc) and primary sclerosing cholangitis (psc). in primary biliary cirrhosis ursodeoxycholic acid improves liver enzymes and igm and prevents worsening of liver histology in patients with less advanced forms of the disease, i.e. serum bilirubin less that 2 mg/dl and histologic changes in liver confined to the portal regions. prevention of complications of chronic liver disease has not been established.

Evropska unija - angleščina - EMA (European Medicines Agency)

theravia - cholic acid - digestive system diseases; metabolism, inborn errors - bile acids and derivatives - orphacol is indicated for the treatment of inborn errors in primary bile-acid synthesis due to 3β-hydroxy-Δ5-c27-steroid oxidoreductase deficiency or Δ4-3-oxosteroid-5β-reductase deficiency in infants, children and adolescents aged one month to 18 years and adults.

Evropska unija - angleščina - EMA (European Medicines Agency)

advanz pharma limited - obeticholic acid - liver cirrhosis, biliary - bile and liver therapy - ocaliva is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca or as monotherapy in adults unable to tolerate udca.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - ursodeoxycholic acid, quantity: 250 mg - capsule, hard - excipient ingredients: povidone; sodium lauryl sulfate; maize starch; magnesium stearate; titanium dioxide; gelatin; purified water - treatment of chronic cholestatic liver diseases.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - obeticholic acid, quantity: 5 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - ocaliva is indicated for the treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca or as monotherapy in adults unable to tolerate udca.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - obeticholic acid, quantity: 10 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - ocaliva is indicated for the treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca or as monotherapy in adults unable to tolerate udca.

Kenija - angleščina - Pharmacy and Poisons Board

beacon medicare limited 9/b/2, toyenbee circular road, motijheel, - obeticholic acid inn - tablet - obeticholic acid 5mg - obeticholic acid

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - chenodeoxycholic acid - capsule - 250mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - chenodeoxycholic acid - tablet - 200mg